1. Insights Into the Spectrum of Tardive Dyskinesia

3. What Is Tardive Dyskinesia?

4. TD Is Still a Concern

5. Epidemiology of TD

6. Comprehensive TD Prevalence Meta-Analysis

7. Prevention of TD

8. Monitoring Movement Disorders in Patients Taking Antipsychotics

9. AIMS: The Standard of Care

10. Tardive Syndromes

11. Risk Factors for TD

12. Differential Diagnosis

13. Schooler-Kane Research Criteria for TD Diagnosis

14. Treatment of TD

15. Tetrabenazine

16. VMAT2

17. Valbenazine (NBI-98854)

18. Valbenazine vs Placebo KINECT 3: Phase 3 Trial

19. Valbenazine AEs

20. Valbenazine for TD KINECT 3: Phase 3 Trial

21. An Agent in Development for TD: Deutetrabenazine

22. Deutetrabenazine

23. Deutetrabenazine vs Placebo Phase 3 Trial

24. Deutetrabenazine AEs

25. Conclusions

26. Abbreviations